Posts Tagged ‘biotechnology’

How To Determine Whether Your IT System Is Regulated

A couple weeks back, I launched a brief blog series about assessing and mitigating risk with regulated IT systems. This week’s post will cover the first part in a four-part approach you can use to do just that: assess and mitigate risk. Part One: System Regulated Status The first step is to determine whether a […]

Obamacare Repeal Could Fuel Pharma And Biotech Acquisitions

Just last week, the house voted to repeal Obamacare, and much has already been covered in articles readily available on the internet. But the Senate has already stated they will write up new legislation that will take into consideration the House bill. No timeline for the Senate to produce its new legislation has been set, […]

It’s Official: Dr. Scott Gottlieb To Lead FDA

One of the key issues and perspectives we outlined in our recent State of the Life Sciences Industry guide was President Trump’s intention to reform the Food and Drug Administration (FDA) through the elimination or significant modification of regulations. Part of his recipe for reforming the FDA included bringing in a new head of the […]

Happy May Day! Top 5 Life Sciences Blog Posts From April 2017

Happy May Day! Now that May is here, I thought it would be neat to look back at what our readers found most interesting last month. Below are the top five blog posts Perficient’s life sciences practice wrote in April – they’re ranked in order of popularity, with number one being the most viewed piece. My Colleagues […]

[Webinar] Upgrading Siebel Clinical To IP2016 & Preview Of IP2017

Because Siebel Innovation Pack (IP) 2016 was such a significant departure from previous Siebel versions, our clinical operations team devoted much of last year to beta testing it, helping Oracle identify and iron out the kinks. Now that we have finished our assessment of the risks and rewards of upgrading Siebel Clinical to IP2016, we […]

New Guide On Modernizing Clinical Trials With Digital Experiences

The industry is all a-buzz with digital engagement initiatives for patients, but let’s not forget about clinical subjects and even site personnel. They’re technology consumers, just like the rest of us, and they crave clinical trials that are simple, easy, convenient, and engaging. As an advocate for sites and subjects, Perficient just published a guide […]

Duke & FDA Study On Investigator Retention Shows 54% Turnover

Last month, Duke University and the FDA released the results of a jointly conducted study on principal investigator (PI) retention. The study was released early online, but the print version is being published in June in the journal of Contemporary Clinical Trials Communications, published by Elsevier. The purpose of the study was two-fold: 1) to […]

[Guide] The State Of The Life Sciences Industry

Last year’s presidential election invoked a great deal of angst in the pharmaceutical industry, with the cost of drugs taking center stage for a good portion of some candidates’ campaigns. While the things candidates said they would do could very well be different from what they might actually do, their words and records were enough […]

Fortune’s 6 Best Life Sciences Companies To Work For

Fortune just released their list of the 100 best companies to work for in America. The survey, which was compiled by Great Places to Work, generated feedback from over 230,000 individuals. The data collected and analyzed took into consideration a variety of aspects that have the potential to influence people’s feelings towards their workplace, including […]

The Trump Administration’s Impact On Pharma

There are plenty of articles out there about how the pharmaceutical industry may be affected by Donald Trump’s presidency. The problem is that nobody exactly knows how things are going to pan out over the next few years. When it comes to health insurance, the price of drugs, and the quality of providers across the entire health […]

Asset Management In Life Sciences

My colleague, Chris Bangma, published a blog post last week that touches on how IBM Maximo, a comprehensive asset management system for managing physical assets, can comply with the FDA’s 21 CFR Part 11 regulation. In particular, he highlights three key areas of the rule that governs the use of electronic records and electronic signatures […]

Digital Technology In The Subject Screening Process

Subject screening adds significant cost to a trial, so it’s an ideal process to try to streamline. Subjects who don’t meet eligibility requirements ultimately lower the efficiency and ROI of a trial, since time and money was spent on those assessments. The screening process is one area that presents an opportunity for cost-savings, whether it […]

Load More